WO2022111793A1 - Médicament destiné à accélérer la cicatrisation - Google Patents

Médicament destiné à accélérer la cicatrisation Download PDF

Info

Publication number
WO2022111793A1
WO2022111793A1 PCT/EP2020/083190 EP2020083190W WO2022111793A1 WO 2022111793 A1 WO2022111793 A1 WO 2022111793A1 EP 2020083190 W EP2020083190 W EP 2020083190W WO 2022111793 A1 WO2022111793 A1 WO 2022111793A1
Authority
WO
WIPO (PCT)
Prior art keywords
peg
sodium
dimethicone
acid
ppg
Prior art date
Application number
PCT/EP2020/083190
Other languages
English (en)
Inventor
Marcus Rudolf Götz
Uwe SCHAAR
Emilie Singer
Michael DOSSI
Original Assignee
Symrise Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symrise Ag filed Critical Symrise Ag
Priority to PCT/EP2020/083190 priority Critical patent/WO2022111793A1/fr
Publication of WO2022111793A1 publication Critical patent/WO2022111793A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • the present invention refers to the area of pharmaceutical compositions and relates to specific medicaments for accelerating wound healing.
  • Wound healing refers to the body's endogenous process of closing a wound by re storing the damaged body tissue to the greatest possible extent. This is a natural biological process that begins only minutes after occurrence of the wound, as has been established by enzyme histochemical methods. The platelets are sent to the damaged site and attempt to close it. In some cases, scab formation occurs by exudation (secretion of fluid), which also causes the itching frequently accompanying wound healing.
  • Wound healing can be divided into various phases. Initially, after the destroyed blood vessel is closed by a clot, there are no further macroscopically or microscopically visible reac tions. This first latency phase leads into an exudation phase, in which foreign bodies and bac teria are washed from the wound by wound secretion exuding from the wound. In this phase, the cells and hormones of the immune system play an essential role, not only in killing bacte ria or viruses that have invaded the wound, but also in stimulating the healing process itself. In clot formation, a fibrin network is formed that acts as an adhesive to close adjacent mar gins of the wound. Clear wound secretion composed of serum is permeated with inflamma tory cells.
  • the wound defect is increasingly filled by prolif eration of new connective tissue.
  • the fibrin network is broken down (fibrinolysis) by plasmin.
  • Vascularization i.e. an increase in the number of blood vessels, takes place by capillary growth.
  • the fibroblasts produce hex- osamine-containing acidic mucopolysaccharides, which function as an extracellular base sub stance of the connective tissue and, via intracellular preliminary stages, form the final extra cellular collagen connective tissue fibers.
  • the process over time is highly complex and is sub ject to the influence of numerous growth factors (cytokines).
  • the wound is closed at the surface by epithelializa- tion.
  • One-third of the diameter of a well-granulating wound closes exclusively by contraction, and the other two-thirds close due to reformation or cell division of epithelial cells and mi gration via fibrin from the wound margin to the center of the wound.
  • the underlying granu lation tissue increasingly forms collagen fibers, after which restoration of all skin layers is vir tually complete.
  • the further increase in the strength of the scar tissue depends on moisten ing, solidifying, and orientation of the collagen fibers.
  • the water content of the tissue de creases, and the scar, which initially protruded slightly above skin level, normally contracts to below skin level.
  • the vascularity of the scar tissue also decreases.
  • the originally fresh red scar turns white.
  • EP 0967980 B1 (YORK PHARMA) suggests substituted 2-aminothiazoles for promot ing wound healing.
  • EP 1070058 B1 (PFIZER) relates to arylsulfoaminopyran carboxylic acid hydroxymides useful for accelerating wound healing and treating burns.
  • EP 1387838 B1 (BAYER) concerns anthranilamide pyridinamides as VEGFR-2 and VEGFR-3 inhibitors, their production and use as pharmaceutical agents for treating injuries
  • EP 1392354 B1 (BAYER) relates to the use of alpha 1-antichymotrypsin (ACT) poly peptides and/or nucleic acids encoding them, or an antibody or a fragment thereof directed against the polypeptide, or of a cell which is expressing the polypeptide or a nucleic acid en coding it, for treatment and/or prevention of diabetes-associated and/or arterial wounds which heal poorly and for identifying pharmacologically active substances which exert an influence on the expression or function, particularly the activity of ACT.
  • ACT alpha 1-antichymotrypsin
  • EP 1877396 B1 suggests novel dipyridyl-dihydropyrazolones, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for promoting wound healing.
  • CN 106511250 A (JINGXI YIXINTANG) suggests a complex mixture of low volatile essential oils for promoting wound gealing.
  • WO 2015 193262 A1 (SYMRISE) relates to sandalore and brahmanol as medicaments for accelerated wound healing.
  • the object of the present invention has been identifying sub stance groups or concrete substances capable of promoting wound healing, preferably by accelerating wound coherence.
  • a first object of the present invention refers to a agonists of olfactory receptors, par ticularly OR2AT4, showing a molecular weight ranging from about 50 to about 300 Dalton, preferably from about 75 to about 250 Dalton and an evaporation rate versus butyl acetate of about 3 to about 15, preferably from about 5 to about 10, for use as a medicament for accelerating wound healing.
  • Olfactory receptors also known as odorant receptors, are expressed in the cell membranes of olfactory receptor neurons and are responsible for the detection of air-borne odour molecules that enter the nasal cavity. Activated olfactory receptors trigger nerve im pulses which transmit information about odour to the brain. These receptors are members of the class A rhodopsin-like family of G protein-coupled receptors (G PC Rs). The olfactory re ceptors form a multigene family consisting of around 800 genes in humans. Particularly, the human nose has roughly 400 types of scent receptors that can detect at least 1 trillion different odours.
  • olfactory receptors display affinity for a range of odour molecules, and conversely a single odorant molecule may bind to a number of ol factory receptors with varying affinities, which depend on physio-chemical properties of mol- ecules like their molecular volumes.
  • the receptor undergoes structural changes and it binds and activates the olfactory-type G pro tein on the inside of the olfactory receptor neuron.
  • the G protein (G 0if and/or G s ) in turn acti vates the lyase - adenylate cyclase - which converts ATP into cyclic AMP (cAMP).
  • the cAMP opens cyclic nucleotide-gated ion channels which allow calcium and sodium ions to enter into the cell, depolarizing the olfactory receptor neuron and beginning an action poten tial which carries the information to the brain.
  • OR is the root name (Olfactory Receptor superfamily)
  • n an integer representing a family (e.g., 1-56) whose members have greater than 40% sequence identity
  • OR1A1 is the first isoform of subfamily A of olfactory receptor family.
  • An overview on olfactory receptors can be found in the following paper submitted by Gaillard I, Rouquier S, Giorgi: D "Olfactory receptors”. Cellular and Molecular Life Sciences. 61 (4): 456-69 (2004).
  • the evaporation rate is the rate at which a material will vaporize (evaporate, change from liquid to vapor) compared to the rate of vaporization of butyl acetate, which is set as 1. This quantity is a ratio, therefore it is unitless.
  • Suitable agonists according to the present invention are selected from the group con sisting of:
  • the preferred agonists show an aldehyde, ketone, ester or terpene structure.
  • the agonists can be applied in a concentration of from 0.1 to 100 pg/ml, and prefera bly of from 0.5 to 10 pg/ml.
  • Another object of the present invention refers to a cosmetic or pharmaceutical com position comprising the agonists as defined above, preferably in amounts of from 0.0001 to about 1 wt. -percent, more preferably from about 0.001 to about 0.1 wt.-percent and most preferred from about 0.02 to 0.05 wt.-percent.
  • compositions may represent a lotion, a cream, an emulsion, an ointment, a stick, an aerosol or a spray or any other form for topical application on skin.
  • compositions may comprise a cosmetically or phar maceutically acceptable carrier or solvent, such as for example water, ethanol, isopropyl alco hol, butanol, glycerol, ethylene glycol, propylene glycol and diethylene glycol or mixtures thereof.
  • a cosmetically or phar maceutically acceptable carrier or solvent such as for example water, ethanol, isopropyl alco hol, butanol, glycerol, ethylene glycol, propylene glycol and diethylene glycol or mixtures thereof.
  • the carriers may be present in quantities of 99 wt.-percent, preferably 99.9 wt.- percent or more.
  • Anti-inflammatory agents such as for example water, ethanol, isopropyl alco hol, butanol, glycerol, ethylene glycol, propylene glycol and diethylene glycol or mixtures thereof.
  • the carriers may be present in quantities of 99 wt.-percent, preferably 99.9 wt.
  • compositions may comprise at least one anti inflammatory agent, in particular steroidal substances of the corticosteroid type selected from the group consisting of hydrocortisone, dexamethasone, dexamethasone phosphate, methyl prednisolone or cortisone, are advantageously used as anti-inflammatory active in gredients or active ingredients to relieve reddening and itching, the list of which can be ex tended by the addition of other steroidal anti-inflammatories.
  • Non-steroidal anti inflammatories can also be used. More particularly:
  • steroidal anti-inflammatory substances of the corticosteroid type in particular hydro cortisone, hydrocortisone derivatives such as hydrocortisone 17-butyrate, dexame thasone, dexamethasone phosphate, methylprednisolone or cortisone,
  • non-steroidal anti-inflammatory substances in particular oxicams such as piroxicam or tenoxicam, salicylates such as aspirin, disalcid, solprin or fendosal, acetic acid deriv atives such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin or clindanac, fenamates such as mefenamic, meclofenamic, flufenamic or niflumic, propionic acid derivatives such as ibuprofen, naproxen or benoxaprofen, pyrazoles such as phenyl butazone, oxyphenylbutazone, febrazone or azapropazone,
  • oxicams such as piroxicam or tenoxicam
  • salicylates such as aspirin, disalcid, solprin or fendosal
  • acetic acid deriv atives such as diclofenac, fenclo
  • histamine receptor antagonists include serine protease inhibitors (e.g. of Soy extracts), TRPV1 antagonists (e.g. 4-t-Butylcyclohexanol), NK1 antagonists (e.g. Aprepitant, Hydroxy- phenyl Propamidobenzoic Acid), cannabinoid receptor agonists (e.g. Palmitoyl Ethan- olamine) and TRPV3 antagonists.
  • serine protease inhibitors e.g. of Soy extracts
  • TRPV1 antagonists e.g. 4-t-Butylcyclohexanol
  • NK1 antagonists e.g. Aprepitant, Hydroxy- phenyl Propamidobenzoic Acid
  • cannabinoid receptor agonists e.g. Palmitoyl Ethan- olamine
  • TRPV3 antagonists e.g. Palmitoyl Ethan- olamine
  • oxicams such as piroxicam or tenoxicam
  • salicy lates such as aspirin, disalcid, solprin or fendosal
  • acetic acid derivatives such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin or clindanac
  • fenamates such as mefenamic, meclofenamic, flufenamic or niflumic
  • propionic acid derivatives such as ibuprofen, naproxen, benoxaprofen or pyrazoles such as phenylbutazone, oxyphenylbutazone, febrazone or azapropazone.
  • Anthranilic acid derivatives in particular avenanthramides described in WO 2004 047833 Al, are also preferred in a composition according to the present invention.
  • bisabolol when used in the context of the present invention it can be of natural or synthetic origin, and is preferably "alpha-bisabolol".
  • the bisabolol used is syn thetically prepared or natural (-)-alpha-bisabolol and/or synthetic mixed-isomer alpha- bisabolol.
  • natural (-)-alpha-bisabolol is used, this can also be employed as a constituent of an essential oil or of a plant extract or of a fraction thereof, for example as a constituent of (fractions of) oil or extracts of camomile or of Vanillosmopsis (in particular Vanillosmopsis erythropappa or Vanillosmopsis arborea).
  • Synthetic alpha-bisabolol is obtainable, for exam ple, under the name "Dragosantol" from Symrise.
  • ex tracts of the fresh or dried ginger root are used which are prepared by extraction with meth anol, ethanol, iso-propanol, acetone, ethyl acetate, carbon dioxide (C02), hexane, methylene chloride, chloroform or other solvents or solvent mixtures of comparable polarity.
  • the ex tracts are characterized by the presence of active skin irritation-reducing amounts of constit uents such as e.g. gingerols, shogaols, gingerdiols, dehydrogingerdiones and/or paradols.
  • agonists according to the present invention are incorporated in or deliv ered to the wound by means of a cosmetic or pharmaceutical composition, these may con tain further additives which are typical for skin care applications, as for example:
  • auxiliaries and additives are anionic and/or amphoteric or zwitterionic sur factants.
  • Non-ionic and cationic surfactants can be also present in the composition. Suitable examples are mentioned along with the paragraph dealing with emulsifiers.
  • Typical examples for anionic and zwitterionic surfactants encompass: Almondami- dopropylamine Oxide, Almondamidopropyl Betaine, Aminopropyl Laurylglutamine, Ammoni um C12-15 Alkyl Sulfate, Ammonium C12-16 Alkyl Sulfate, Ammonium Capryleth Sulfate, Ammonium Cocomonoglyceride Sulfate, Ammonium Coco-Sulfate, Ammonium Cocoyl Isethionate, Ammonium Cocoyl Sarcosinate, Ammonium C12-15 Pareth Sulfate, Ammonium C9-10 Perfluoroalkylsulfonate, Ammonium Dinonyl Sulfosuccinate, Ammonium Dodecylben- zenesulfonate, Ammonium Isostearate, Ammonium Laureth-6 Carboxylate, Ammonium Lau- reth-8 Carboxylate, Ammonium Laureth S
  • the percentage content of surfactants in the preparations may be from 0.1 to 10% by weight and is preferably from 0.5 to 5% by weight, based on the preparation.
  • Suitable oil bodies which form constituents of the O/W emulsions, are, for example, Guerbet alcohols based on fatty alcohols having 6 to 18, preferably 8 to 10, carbon atoms, esters of linear C 6 -C 22 -fatty acids with linear or branched C 6 -C 22 -fatty alcohols or esters of branched C 6 -C 13 -carboxylic acids with linear or branched C 6 -C 22 -fatty alcohols, such as, for example, myristyl myristate, myristyl palmitate, myristyl stearate, myristyl isostearate, myristyl oleate, myristyl behenate, myristyl erucate, cetyl myristate, cetyl palmitate, cetyl stearate, ce tyl isostearate, cetyl oleate, cetyl behenate, cetyl erucate, stearate, ce
  • esters of linear C 6 -C 22 -fatty acids with branched alcohols in particular 2-ethylhexanol, esters of C 18 -C 38 - alkylhydroxy carboxylic acids with linear or branched C 6 -C 22 -fatty alcohols, in particular Dioctyl Malate, esters of linear and/or branched fatty acids with polyhydric alcohols (such as, for example, propylene glycol, dimerdiol or trimertriol) and/or Guerbet alcohols, triglycerides based on Ce -Cio-fatty acids, liquid mono-/di-/triglyceride mixtures based on C 6 -Cis-fatty acids, esters of Ce- C 22 -fatty al cohols and/or Guerbet alcohols with aromatic carboxylic acids, in particular benzoic acid, es ters of C 2 - Ci 2 -dicarboxylic acids with linear or branched alcohols having 1 to 22
  • Finsolv® TN linear or branched, sym metrical or asymmetrical dialkyl ethers having 6 to 22 carbon atoms per alkyl group, such as, for example, dicaprylyl ether (Cetiol® OE), ring-opening products of epoxidized fatty acid esters with polyols, silicone oils (cyclomethicones, silicone methicone grades, etc.) and/or aliphatic or naphthenic hydrocarbons, such as, for example, squalane, squalene or dialkylcy- clohexanes.
  • dicaprylyl ether such as, for example, dicaprylyl ether (Cetiol® OE), ring-opening products of epoxidized fatty acid esters with polyols, silicone oils (cyclomethicones, silicone methicone grades, etc.) and/or aliphatic or naphthenic hydrocarbons, such as, for example, s
  • non-ionic or cationic surfactants may also be added to the preparations as emulsifiers, including for example:
  • polyol esters and, in particular, polyglycerol esters such as, for example, polyglycerol polyricinoleate, polyglycerol poly-12-hydroxystearate or polyglycerol dimerate isos tearate. Mixtures of compounds from several of these classes are also suitable;
  • Partial glycerides Typical examples of suitable partial glycerides are hydroxystearic acid monoglyceride, hydroxystearic acid diglyceride, isostearic acid monoglyceride, isostearic acid diglyceride, oleic acid monoglyceride, oleic acid diglyceride, ricinoleic acid monoglycer ide, ricinoleic acid diglyceride, linoleic acid monoglyceride, linoleic acid diglyceride, linolenic acid monoglyceride, linolenic acid diglyceride, erucic acid monoglyceride, erucic acid diglyc eride, tartaric acid monoglyceride, tartaric acid diglyceride, citric acid monoglyceride, citric acid diglyceride, malic acid monoglyceride, malic acid diglyceride and technical mixtures thereof which may still contain small quantities of
  • Sorbitan esters are sorbitan monoisostearate, sorbitan ses- quiisostearate, sorbitan diisostearate, sorbitan triisostearate, sorbitan monooleate, sorbitan sesquioleate, sorbitan dioleate, sorbitan trioleate, sorbitan monoerucate, sorbitan sesquieru- cate, sorbitan dierucate, sorbitan trierucate, sorbitan monoricinoleate, sorbitan sesquiricino- leate, sorbitan diricinoleate, sorbitan triricinoleate, sorbitan monohydroxystearate, sorbitan sesquihydroxystearate, sorbitan dihydroxystearate, sorbitan trihydroxystearate, sorbitan monotartrate, sorbitan sesquitartrate, sorbitan ditartrate, sorbitan tritartrate, sorbitan monotartrate, sorb
  • Polyglycerol esters are Polyglyceryl- 2 Dipolyhydroxystearate (Dehymuls ® PGPH), Polyglycerin-3-Diisostearate (Lameform ® TGI), Polyglyceryl-4 Isostearate (Isolan ® GI 34), Polyglyceryl-3 Oleate, Diisostearoyl Polyglyceryl-3 Diisostearate (Isolan® PDI), Polyglyceryl-3 Methylglucose Distearate (Tego Care ® 450), Poly- glyceryl-3 Beeswax (Cera Beilina ® ), Polyglyceryl-4 Caprate (Polyglycerol Caprate T2010/90), Polyglyceryl-3 Cetyl Ether (Chimexane ® NL), Polyglyceryl-3 Distearate (Cremophor® GS 32) and Polyglyceryl Polyricino
  • polystyrene resin examples include the mono-, di- and triesters of trimethylol propane or pentaerythritol with lauric acid, cocofatty acid, tallow fatty acid, pal mitic acid, stearic acid, oleic acid, behenic acid and the like optionally reacted with 1 to 30 mol ethylene oxide.
  • Cationically active surfactants comprise the hydrophobic high molecular group required for the surface activity in the cation by dissociation in aqueous solution.
  • a group of important representatives of the cationic surfactants are the tetraalkyl ammonium salts of the general formula: (R 1 R 2 R 3 R 4 N + ) X .
  • R1 stands for Ci-Cs alk(en)yl, R 2 , R 3 and R 4 , independently of each other, for alk(en)yl radicals having 1 to 22 carbon atoms.
  • X is a counter ion, preferably selected from the group of the halides, alkyl sulfates and alkyl carbonates.
  • Cationic surfactants, in which the nitrogen group is substituted with two long acyl groups and two short alk(en)yl groups are particularly preferred.
  • Esterquats A further class of cationic surfactants particularly useful as co-surfactants for the present invention is represented by the so-called esterquats.
  • Esterquats are generally understood to be quaternised fatty acid triethanolamine ester salts. These are known compounds which can be obtained by the relevant methods of preparative organic chemistry. Reference is made in this connection to International patent application WO 91/01295 Al, according to which triethanolamine is partly esterified with fatty acids in the presence of hypophosphorous acid, air is passed through the reaction mixture and the whole is then quaternised with dimethyl sulphate or ethylene oxide.
  • German patent DE 4308794 Cl describes a process for the production of solid esterquats in which the quaternisation of triethanolamine esters is carried out in the presence of suitable dispersants, preferably fatty alcohols.
  • esterquats suitable for use in accordance with the invention are products of which the acyl component derives from monocarboxylic acids corresponding to formula RCOOH in which RCO is an acyl group containing 6 to 10 carbon atoms, and the amine component is triethanolamine (TEA).
  • monocarboxylic acids are caproic acid, caprylic acid, capric acid and technical mixtures thereof such as, for example, so- called head-fractionated fatty acid.
  • Esterquats of which the acyl component derives from monocarboxylic acids containing 8 to 10 carbon atoms are preferably used.
  • esterquats are those of which the acyl component derives from dicarboxylic acids like malonic acid, succinic acid, maleic acid, fumaric acid, glutaric acid, sorbic acid, pimelic acid, azelaic acid, sebacic acid and/or dodecanedioic acid, but preferably adipic acid.
  • esterquats of which the acyl component derives from mixtures of monocarboxylic acids containing 6 to 22 carbon atoms, and adipic acid are preferably used.
  • the molar ratio of mono and dicarboxylic acids in the final esterquat may be in the range from 1:99 to 99:1 and is preferably in the range from 50:50 to 90:10 and more particularly in the range from 70:30 to 80:20.
  • other suitable esterquats are quaternized ester salts of mono-/dicarboxylic acid mixtures with diethanolalkyamines or 1,2- dihydroxypropyl dialkylamines.
  • the esterquats may be obtained both from fatty acids and from the corresponding triglycerides in admixture with the corresponding dicarboxylic acids.
  • Superfatting agents may be selected from such substances as, for example, lanolin and lecithin and also polyethoxylated or acylated lanolin and lecithin derivatives, polyol fatty acid esters, monoglycerides and fatty acid alkanolamides, the fatty acid alkanolamides also serving as foam stabilizers.
  • the consistency factors mainly used are fatty alcohols or hydroxyfatty alcohols con taining 12 to 22 and preferably 16 to 18 carbon atoms and also partial glycerides, fatty acids or hydroxyfatty acids.
  • a combination of these substances with alkyl oligoglucosides and/or fatty acid N-methyl glucamides of the same chain length and/or polyglycerol poly-12- hydroxystea rates is preferably used.
  • Suitable thickeners are polymeric thickeners, such as Aerosil® types (hydrophilic sili cas), polysaccharides, more especially xanthan gum, guar-guar, agar-agar, alginates and tylo ses, carboxymethyl cellulose and hydroxyethyl cellulose, also relatively high molecular weight polyethylene glycol monoesters and diesters of fatty acids, polyacrylates (for example Carbo- pols® [Goodrich] or Synthalens® [Sigma]), polyacrylamides, polyvinyl alcohol and polyvinyl pyrrolidone, surfactants such as, for example, ethoxylated fatty acid glycerides, esters of fatty acids with polyols, for example pentaerythritol or trimethylol propane, narrow-range fatty alcohol ethoxylates and electrolytes, such as sodium chloride and ammonium chloride.
  • Aerosil® types hydrophilic sili cas
  • Suitable cationic polymers are, for example, cationic cellulose derivatives such as, for example, the quaternized hydroxyethyl cellulose obtainable from Amerchol under the name of Polymer JR 400®, cationic starch, copolymers of diallyl ammonium salts and acrylamides, quaternized vinyl pyrrolidone/vinyl imidazole polymers such as, for example, Luviquat® (BASF), condensation products of polyglycols and amines, quaternized collagen polypeptides such as, for example, Lauryldimonium Hydroxypropyl Hydrolyzed Collagen (Lamequat® L, GrOnau), quaternized wheat polypeptides, polyethyleneimine, cationic silicone polymers such as, for example, amodimethicone, copolymers of adipic acid and dimethylaminohy- droxypropyl diethylenetriamine (Carta retine ® , Sando
  • Suitable anionic, zwitterionic, amphoteric and nonionic polymers are, for example, vinyl acetate/crotonic acid copolymers, vinyl pyrrolidone/vinyl acrylate copolymers, vinyl ace tate/butyl maleate/isobornyl acrylate copolymers, methyl vinylether/maleic anhydride copol ymers and esters thereof, uncrosslinked and polyol-crosslinked polyacrylic acids, acrylamido- propyl trimethylammonium chloride/acrylate copolymers, octylacrylamide/methyl methacry- late/tert.-butylaminoethyl methacrylate/2-hydroxypropyl methacrylate copolymers, polyvinyl pyrrolidone, vinyl pyrrolidone/vinyl acetate copolymers, vinyl pyrroli- done/dimethylaminoethyl methacrylate/vinyl caprol
  • Suitable pearlising waxes are, for example, alkylene glycol esters, especially ethylene glycol distearate; fatty acid alkanolamides, especially cocofatty acid diethanolamide; partial glycerides, especially stearic acid monoglyceride; esters of polybasic, optionally hydroxy- substituted carboxylic acids with fatty alcohols containing 6 to 22 carbon atoms, especially long-chain esters of tartaric acid; fatty compounds, such as for example fatty alcohols, fatty ketones, fatty aldehydes, fatty ethers and fatty carbonates which contain in all at least 24 carbon atoms, especially laurone and distearylether; fatty acids, such as stearic acid, hy- droxystearic acid or behenic acid, ring opening products of olefin epoxides containing 12 to 22 carbon atoms with fatty alcohols containing 12 to 22 carbon atoms and/or polyols con ta
  • Suitable silicones can be chosen from the group consisting of: Acefylline Methylsilanol Mannuronate, Acetylmethionyl Methylsilanol Elastinate Acrylates/Behenyl, Acry- late/Dimethicone Methacrylate Copolymer, Acrylates/Behenyl Methacrylate/Dimethicone Methacrylate Copolymer, Acrylates/Bis-Hydroxypropyl Dimethicone Crosspolymer, Acry- lates/Dimethicone Copolymer, Acrylates/Dimethicone Methacrylate/Ethylhexyl Acrylate Co polymer, Acrylates/Dimethiconol Acrylate Copolymer, Acrylates/Ethylhexyl Acry- late/Dimethicone Methacrylate Copolymer, Acrylates/Octylacrylamide/Diphenyl Amodimethi- cone
  • Butyloxyamodimethicone/PEG-60 Copolymer Bis(C13-15 Alkoxy) Hydroxybutamidoamodi- methicone, Bis(C13-15 Alkoxy) PG- Amodimethicone, Bis-(Cl-8 Alkyl Lauroyl Lysine Decyl- carboxamide) Dimethicone, Bis-Cetyl Cetyl Dimethicone, Bis-Cetyl/PEG-8 Cetyl PEG-8 Dime thicone, Bis-Diphenylethyl Disiloxane, Bis-Ethyl Ethyl Methicone, Bis- Gluconamidoethylaminopropyl Dimethicone, Bis-Hydrogen Dimethicone, Bis- Hydroxyethox- ypropyl Dimethicone Bis-Hydroxylauryl, Dimethicone/IPDI Copolymer, Bis- Hydroxy/Methoxy Amodimethicon
  • silicones to be contained in the mixture according to the inven tions are Dimethicone, Cyclomethicone, Phenyl Trimethicone, Cyclohexasiloxane and Cyclo- pentasiloxane.
  • Dimethicone Cyclomethicone
  • Phenyl Trimethicone Phenyl Trimethicone
  • Cyclohexasiloxane Cyclo- pentasiloxane
  • waxes may also be present in the preparations, more espe cially natural waxes such as, for example, candelilla wax, carnauba wax, Japan wax, espar- tograss wax, cork wax, guaruma wax, rice oil wax, sugar cane wax, ouricury wax, montan wax, beeswax, shellac wax, spermaceti, lanolin (wool wax), uropygial fat, ceresine, ozocerite (earth wax), petrolatum, paraffin waxes and microwaxes; chemically modified waxes (hard waxes) such as, for example, montan ester waxes, sasol waxes, hydrogenated jojoba waxes and syn thetic waxes such as, for example, polyalkylene waxes and polyethylene glycol waxes.
  • candelilla wax carnauba wax, Japan wax, espar- tograss wax, cork wax, guaruma wax, rice oil wax
  • Metal salts of fatty acids such as, for example, magnesium, aluminium and/or zinc stearate or ricinoleate may be used as stabilizers.
  • Primary sun protection factors in the context of the invention are, for example, organ ic substances (light filters) which are liquid or crystalline at room temperature and which are capable of absorbing ultraviolet radiation and of releasing the energy absorbed in the form of longer-wave radiation, for example heat.
  • organ ic substances light filters
  • light filters which are liquid or crystalline at room temperature and which are capable of absorbing ultraviolet radiation and of releasing the energy absorbed in the form of longer-wave radiation, for example heat.
  • the formulations according to the invention advantageously contain at least one UV- A filter and/or at least one UV-B filter and/or a broadband filter and/or at least one inorganic pigment.
  • Formulations according to the invention preferably contain at least one UV-B filter or a broadband filter, more particularly preferably at least one UV-A filter and at least one UV-B filter.
  • Preferred cosmetic compositions preferably topical formulations according to the present invention comprise one, two, three or more sun protection factors selected from the group consistiung of 4-aminobenzoic acid and derivatives, salicylic acid derivatives, benzo- phenone derivatives, dibenzoylmethane derivatives, diphenyl acrylates, 3-imidazol-4-yl acryl ic acid and esters thereof, benzofuran derivatives, benzylidene malonate derivatives, poly meric UV absorbers containing one or more organosilicon radicals, cinnamic acid derivatives, camphor derivatives, trianilino-s-triazine derivatives, 2-hydroxyphenylbenzotriazole deriva- tives, phenylbenzimidazole sulfonic acid derivatives and salts thereof, anthranilic acid menthyl esters, benzotriazole derivativesand indole derivatives.
  • sun protection factors selected from the group consistiung of 4-aminobenz
  • UV filters cited below which can be used within the context of the present inven tion are preferred but naturally are not limiting.
  • UV filters which are preferably used are selected from the group consisting of p-aminobenzoic acid p-aminobenzoic acid ethyl ester (25 mol) ethoxylated (INCI name: PEG-25 PABA) p-dimethylaminobenzoic acid-2-ethylhexyl ester p-aminobenzoic acid ethyl ester (2 mol) N-propoxylated p-aminobenzoic acid glycerol ester salicylic acid homomenthyl ester (homosalates) (Neo Heliopan ® HMS) salicylic acid-2-ethylhexyl ester (Neo Heliopan ® OS) triethanolamine salicylate
  • Broadband filters which are preferably combined with one or more compounds of formula (I) in a preparation according to the present invention are selected from the group consisting of
  • compositions can comprise further typical detergent and cleansing composition ingredients such as UV-A filters filters which are preferably combined with one or more com pounds of formula (I) in a preparation according to the present invention are selected from the group consisting of
  • compositions can comprise further typical detergent and cleansing composition ingredients such as UV filters which are more preferably combined with one or more com pounds of formula (I) in a preparation according to the present invention are selected from the group consisting of
  • these preparations contain at least one UVA filter and/or at least one UVB filter and/or at least one inorganic pigment.
  • the preparations may be present here in various forms such as are conventionally used for sun protection prepara tions. Thus, they may be in form of a solution, an emulsion of the water-in-oil type (W/O) or of the oil-in-water type (O/W) or a multiple emulsion, for example of the water-in-oil-in- water type (W/O/W), a gel, a hydrodispersion, a solid stick or else an aerosol.
  • a formulation according to the invention contains a total amount of sunscreen agents, i.e. in particular UV filters and/or inorganic pigments (UV filtering pigments) so that the formulation according to the invention has a light protection factor of greater than or equal to 2 (preferably greater than or equal to 5).
  • sunscreen agents i.e. in particular UV filters and/or inorganic pigments (UV filtering pigments) so that the formulation according to the invention has a light protection factor of greater than or equal to 2 (preferably greater than or equal to 5).
  • UV filters and/or inorganic pigments UV filtering pigments
  • Secondary sun protection factors of the antioxidant type interrupt the photochemical reaction chain which is initiated when UV rays penetrate into the skin.
  • Typical examples are amino acids (for example glycine, histidine, tyrosine, tryptophane) and derivatives thereof, imidazoles (for example urocanic acid) and derivatives thereof, peptides, such as D,L-carnosine, D-carnosine, L-carnosine and derivatives thereof (for example anserine), carotinoids, carotenes (for example alpha- carotene, beta-carotene, lycopene) and derivatives thereof, chlorogenic acid and derivatives thereof, liponic acid and derivatives thereof (for example dihydroliponic acid), aurothioglu- cose, propylthiouracil and other thiols (for example thioredoxine, glutathione, cysteine,
  • amino acids for example glycine, histidine, tyrosine, tryptophane
  • Advantageous inorganic secondary light protection pigments are finely dispersed metal oxides and metal salts which are also mentioned in WO 2005 123101 Al.
  • the total quantity of inorganic pigments, in particular hydrophobic inorganic micro-pigments in the finished cosmetic preparation according to the present invention is advantageously from 0.1 to 30% by weight, preferably 0.5 to 10.0% by weight, in each case based on the total weight of the preparation.
  • particulate UV filters or inorganic pigments which can optionally be hydrophobed, can be used, such as the oxides of titanium (T1O 2 ), zinc (ZnO), iron (Fe 2 0s), zirconium (ZrCh), silicon (S1O 2 ), manganese (e.g. MnO), aluminium (AI 2 O 3 ), cerium (e.g. Ce 2 0s) and/or mixtures thereof.
  • compositions may also contain one or more substances with a physiological cool ing effect (cooling agents), which are preferably selected here from the following list: men thol and menthol derivatives (for example L-menthol, D-menthol, racemic menthol, isomen thol, neoisomenthol, neomenthol) menthylethers (for example (I-menthoxy)-l,2-propandiol, (l-menthoxy)-2-methyl-l,2-propandiol, l-menthyl-methylether), menthylesters (for example menthylformiate, menthylacetate, menthylisobutyrate, menthyllactates, L-menthyl-L-lactate, L-menthyl-D-lactate, menthyl-(2-methoxy)acetate, menthyl-(2-methoxyethoxy)acetate, menthylpyroglutamate), menthyl
  • Suitable anti-microbial agents are, in principle, all substances effective against Gram positive bacteria, such as, for example, 4- hydroxybenzoic acid and its salts and esters, N-(4- chlorophenyl)-N'-(3,4- dichlorophenyl)urea, 2,4,4'-trichloro-2'-hydroxy-diphenyl ether (triclo- san), 4-chloro-3, 5-dimethyl-phenol, 2,2'-methylenebis(6-bromo-4- chlorophenol), 3-methyl- 4-(l-methylethyl)phenol, 2-benzyl-4-chloro-phenol, 3-(4-chlorophenoxy)-l, 2-propanediol, 3- iodo-2-propynyl butylcarbamate, chlorhexidine, 3,4,4'-trichlorocarbanilide (TTC), antibacterial fragrances, thymol, thyme oil, eugenol, oil of cloves, ment
  • Suitable preservatives are, for example, phenoxyethanol, formaldehyde solution, parabens, pentanediol or sorbic acid and the other classes of compounds listed in Appendix 6, Parts A and B of the Kosmetikverowski ("Cosmetics Directive").
  • compositions according to the present inventions are selected from the group of products for treatment, protecting, care and cleansing of the skin and/or hair or as a make-up product, preferably as a leave-on product (meaning that the one or more com pounds of formula (I) stay on the skin and/or hair for a longer period of time, compared to rinse-off products, so that the moisturizing and/or anti-ageing and/or wound healing pro moting action thereof is more pronounced).
  • the formulations according to the invention are preferably in the form of an emul sion, e.g. W/O (water-in-oil), O/W (oil-in-water), W/O/W (water-in-oil-in-water), O/W/O (oil- in-water-in-oil) emulsion, PIT emulsion, Pickering emulsion, emulsion with a low oil content, micro- or nanoemulsion, a solution, e.g.
  • a gel including hydrogel, hydrodisper sion gel, oleogel
  • spray e.g. pump spray or spray with propellant
  • a foam or an impreg nating solution for cosmetic wipes e.g. soap, synthetic detergent, liquid wash ing, shower and bath preparation, bath product (capsule, oil, tablet, salt, bath salt, soap, etc.), effervescent preparation, a skin care product such as e.g.
  • an emulsion as described above, ointment, paste, gel (as described above), oil, balsam, serum, powder (e.g. face powder, body powder), eau de perfume, eau de toilette, after-shave, a mask, a pencil, stick, roll-on, pump, aerosol (foaming, non-foaming or post-foaming), a deodorant and/or antiperspirant, mouthwash and mouth rinse, a foot care product (including keratolytic, deodorant), an insect repellent, a sunscreen, aftersun preparation, a shaving product, aftershave balm, pre- and aftershave lotion, a depilatory agent, a hair care product such as e.g.
  • shampoo including 2- in-1 shampoo, anti-dandruff shampoo, baby shampoo, shampoo for dry scalps, concentrated shampoo
  • conditioner hair tonic, hair water, hair rinse, styling creme, pomade, perm and setting lotion
  • hair spray e.g. gel or wax
  • hair smoothing agent detangling agent, relaxer
  • hair dye such as e.g. temporary direct-dyeing hair dye, semi-permanent hair dye, permanent hair dye, hair conditioner, hair mousse, eye care product, make-up, make-up remover or baby product.
  • the formulations according to the invention are particularly preferably in the form of an emulsion, in particular in the form of a W/O, O/W, W/O/W, O/W/O emulsion, PIT emul sion, Pickering emulsion, emulsion with a low oil content, micro- or nanoemulsion, a gel (in cluding hydrogel, hydrodispersion gel, oleogel), a solution e.g. in oil (fatty oils or fatty acid esters, in particular C6-C32 fatty acid C2-C30 esters)) or silicone oil, or a spray (e.g. pump spray or spray with propellant).
  • a spray e.g. pump spray or spray with propellant.
  • Auxiliary substances and additives can be included in quantities of 5 to 99 % b.w., preferably 10 to 80 % b.w., based on the total weight of the formulation.
  • the amounts of cosmetic or dermatological auxiliary agents and additives and perfume to be used in each case can easily be determined by the person skilled in the art by simple trial and error, de pending on the nature of the particular product.
  • the preparations can also contain water in a quantity of up to 99 % b.w., preferably 5 to 80 % b.w., based on the total weight of the preparation
  • Another object of the present invention refers to laminate or plaster into which the agonists according to the present invention are incorporated, for example by impregnation of the part of the laminate or plaster that is applied directly to the wound.
  • Another object of the present invention concerns a non-therapeutical method for accelerating wound healing comprising or consisting of the following steps:
  • the present invention also refers to the use of the agonists as explained above for accelerating wound healing.
  • the present invention also refers to the use of said agonists of olfactory recep tors as cosmetic ingredients.
  • cosmetic ingredients for the sake of good order it is emphasized that all preferred embodiments, ranges, combinations and compositions as described above are also valid with respective to the claimed industrial applications. Any repretition is therefor superfluous.
  • HaCaT keratinocytes maintained in sup- plemented DMEM medium containing 10% FBS and 1% antibiotics penicillin/streptomycin (DMEM complete medium) at 37°C in a humidified atmosphere of 5% CO2.

Abstract

L'invention concerne des agonistes des récepteurs olfactifs, en particulier l'OR2AT4, présentant un poids moléculaire allant d'environ 50 à environ 300 daltons et un taux d'évaporation par rapport à l'acétate de butyle d'environ 3 à environ 15, destinés à être utilisés comme médicament pour accélérer la cicatrisation.
PCT/EP2020/083190 2020-11-24 2020-11-24 Médicament destiné à accélérer la cicatrisation WO2022111793A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2020/083190 WO2022111793A1 (fr) 2020-11-24 2020-11-24 Médicament destiné à accélérer la cicatrisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2020/083190 WO2022111793A1 (fr) 2020-11-24 2020-11-24 Médicament destiné à accélérer la cicatrisation

Publications (1)

Publication Number Publication Date
WO2022111793A1 true WO2022111793A1 (fr) 2022-06-02

Family

ID=73554449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2020/083190 WO2022111793A1 (fr) 2020-11-24 2020-11-24 Médicament destiné à accélérer la cicatrisation

Country Status (1)

Country Link
WO (1) WO2022111793A1 (fr)

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150052A (en) 1971-02-04 1979-04-17 Wilkinson Sword Limited N-substituted paramenthane carboxamides
WO1991001295A1 (fr) 1989-07-17 1991-02-07 Henkel Kommanditgesellschaft Auf Aktien Procede de fabrication de composes quaternaires de l'ammonium
DE4308794C1 (de) 1993-03-18 1994-04-21 Henkel Kgaa Verfahren zur Herstellung von festen Esterquats mit verbesserter Wasserdispergierbarkeit
EP0750606B1 (fr) 1994-03-18 1998-10-28 Henkel Kommanditgesellschaft auf Aktien Procede de production d'esters quaternaires
WO2002038537A1 (fr) 2000-11-10 2002-05-16 Haarmann & Reimer Gmbh Nouveaux composes indanylidene
EP0967980B1 (fr) 1997-01-13 2003-05-02 BaFuS Marketing GmbH Utilisation d'aminothiazoles dans le traitement de plaies ou de la peau
EP1070058B1 (fr) 1998-04-10 2003-05-02 Pfizer Products Inc. Hydroxamides de l'acide (4-arylsulfonylamino)-tetrahydropyrane-4-carboxylique
WO2004026840A1 (fr) 2002-09-18 2004-04-01 Unilever Plc Derives de tetrahydropyrimidine-2-one et leurs utilisations
WO2004047833A2 (fr) 2002-11-25 2004-06-10 Symrise Gmbh & Co. Kg Amides d'acide anthranilique et leurs derives utilises comme principes actifs cosmetiques et pharmaceutiques
EP1392354B1 (fr) 2001-04-30 2005-03-09 Switch Biotech Aktiengesellschaft Utilisation de l'alpha 1-antichymotrypsine pour la preparation d'une composition pour le traitement, la prevention ou le diagnostique des plaies se cicatrisant difficilement associees au diabete
WO2005049553A1 (fr) 2003-11-21 2005-06-02 Givaudan Sa Carboxamides p-menthane a substitution n
WO2005123101A1 (fr) 2004-06-18 2005-12-29 Symrise Gmbh & Co. Kg Extrait de mures sauvages
EP1387838B1 (fr) 2001-05-08 2006-04-19 Schering Aktiengesellschaft Derives de cyanoanthranylamide et leur utilisation comme medicament
WO2007128723A1 (fr) 2006-05-03 2007-11-15 Symrise Gmbh & Co. Kg ANTAGONISTES DES RéCEPTEURS D'AH
EP1877396B1 (fr) 2005-04-28 2009-02-18 Bayer HealthCare AG Derives de 4-(pyridin-3-yl)-2-(pyridin-2-yl)-1,2-dihydro-3h-pyrazol-3-one utilises en tant qu'inhibiteurs specifiques des hif-prolyl-4-hydroxylases pour traiter des maladies cardiovasculaires et hematologiques
EP2033688A2 (fr) 2007-08-20 2009-03-11 Symrise GmbH & Co. KG Dérivés d'acide oxalique et leur utilisation en tant que matières de refroidissement physiologiques
WO2015193262A1 (fr) 2014-06-19 2015-12-23 Symrise Ag Médicament destiné à accélérer la cicatrisation
CN105496867A (zh) * 2015-12-24 2016-04-20 青岛玻莱莫斯新材料技术有限公司 一种促进伤口愈合的沐浴露
CN106511250A (zh) 2016-12-25 2017-03-22 江西宜信堂医疗科技有限公司 一种香水及其制备方法
WO2017058594A1 (fr) * 2015-10-01 2017-04-06 Senomyx, Inc. Composés utiles en tant que modulateurs de trpm8
WO2020182288A1 (fr) * 2019-03-11 2020-09-17 Symrise Ag Procédé d'amélioration de la performance d'un parfum ou d'un mélange de parfums

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150052A (en) 1971-02-04 1979-04-17 Wilkinson Sword Limited N-substituted paramenthane carboxamides
WO1991001295A1 (fr) 1989-07-17 1991-02-07 Henkel Kommanditgesellschaft Auf Aktien Procede de fabrication de composes quaternaires de l'ammonium
DE4308794C1 (de) 1993-03-18 1994-04-21 Henkel Kgaa Verfahren zur Herstellung von festen Esterquats mit verbesserter Wasserdispergierbarkeit
EP0750606B1 (fr) 1994-03-18 1998-10-28 Henkel Kommanditgesellschaft auf Aktien Procede de production d'esters quaternaires
EP0967980B1 (fr) 1997-01-13 2003-05-02 BaFuS Marketing GmbH Utilisation d'aminothiazoles dans le traitement de plaies ou de la peau
EP1070058B1 (fr) 1998-04-10 2003-05-02 Pfizer Products Inc. Hydroxamides de l'acide (4-arylsulfonylamino)-tetrahydropyrane-4-carboxylique
WO2002038537A1 (fr) 2000-11-10 2002-05-16 Haarmann & Reimer Gmbh Nouveaux composes indanylidene
DE10055940A1 (de) 2000-11-10 2002-05-29 Bayer Ag Neue Indanylidenverbindungen
EP1392354B1 (fr) 2001-04-30 2005-03-09 Switch Biotech Aktiengesellschaft Utilisation de l'alpha 1-antichymotrypsine pour la preparation d'une composition pour le traitement, la prevention ou le diagnostique des plaies se cicatrisant difficilement associees au diabete
EP1387838B1 (fr) 2001-05-08 2006-04-19 Schering Aktiengesellschaft Derives de cyanoanthranylamide et leur utilisation comme medicament
WO2004026840A1 (fr) 2002-09-18 2004-04-01 Unilever Plc Derives de tetrahydropyrimidine-2-one et leurs utilisations
WO2004047833A2 (fr) 2002-11-25 2004-06-10 Symrise Gmbh & Co. Kg Amides d'acide anthranilique et leurs derives utilises comme principes actifs cosmetiques et pharmaceutiques
WO2005049553A1 (fr) 2003-11-21 2005-06-02 Givaudan Sa Carboxamides p-menthane a substitution n
WO2005123101A1 (fr) 2004-06-18 2005-12-29 Symrise Gmbh & Co. Kg Extrait de mures sauvages
EP1877396B1 (fr) 2005-04-28 2009-02-18 Bayer HealthCare AG Derives de 4-(pyridin-3-yl)-2-(pyridin-2-yl)-1,2-dihydro-3h-pyrazol-3-one utilises en tant qu'inhibiteurs specifiques des hif-prolyl-4-hydroxylases pour traiter des maladies cardiovasculaires et hematologiques
WO2007128723A1 (fr) 2006-05-03 2007-11-15 Symrise Gmbh & Co. Kg ANTAGONISTES DES RéCEPTEURS D'AH
EP2033688A2 (fr) 2007-08-20 2009-03-11 Symrise GmbH & Co. KG Dérivés d'acide oxalique et leur utilisation en tant que matières de refroidissement physiologiques
WO2015193262A1 (fr) 2014-06-19 2015-12-23 Symrise Ag Médicament destiné à accélérer la cicatrisation
WO2017058594A1 (fr) * 2015-10-01 2017-04-06 Senomyx, Inc. Composés utiles en tant que modulateurs de trpm8
CN105496867A (zh) * 2015-12-24 2016-04-20 青岛玻莱莫斯新材料技术有限公司 一种促进伤口愈合的沐浴露
CN106511250A (zh) 2016-12-25 2017-03-22 江西宜信堂医疗科技有限公司 一种香水及其制备方法
WO2020182288A1 (fr) * 2019-03-11 2020-09-17 Symrise Ag Procédé d'amélioration de la performance d'un parfum ou d'un mélange de parfums

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DANIELA BUSSE ET AL: "A Synthetic Sandalwood Odorant Induces Wound-Healing Processes in Human Keratinocytes via the Olfactory Receptor OR2AT4", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 134, no. 11, 1 November 2014 (2014-11-01), NL, pages 2823 - 2832, XP055534614, ISSN: 0022-202X, DOI: 10.1038/jid.2014.273 *
GAILLARD IROUQUIER SGIORGI: D: "Olfactory receptors", CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 61, no. 4, 2004, pages 456 - 69
LEE SUNG-JOON ET AL: "Therapeutic potential of ectopic olfactory and taste receptors", NATURE REVIEWS DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, vol. 18, no. 2, 30 November 2018 (2018-11-30), pages 116 - 138, XP036688583, ISSN: 1474-1776, [retrieved on 20181130], DOI: 10.1038/S41573-018-0002-3 *
TODD ET AL., COSM. TOIL., vol. 91, 1976, pages 27

Similar Documents

Publication Publication Date Title
KR20210089197A (ko) UV 필터들의 액체이고 투명한 블렌드 (blend)
US20220117881A1 (en) A hair care composition
JP2023552593A (ja) 天然ポリマーおよび１つまたは複数の（バイオ）－アルカンジオールを含む組成物
WO2022122136A1 (fr) Compositions comprenant un ou plusieurs (bio)-alcanediols avec des antioxydants
EP4110476A1 (fr) Compositions comprenant des antimicrobiens et des (bio)-alcanediols pour la protection de la peau
US20230338250A1 (en) Compositions Comprising One or More (Bio)-Alkanediols with Active Ingredients
WO2022111793A1 (fr) Médicament destiné à accélérer la cicatrisation
WO2022161593A1 (fr) Médicament pour la cicatrisation accélérée des plaies
WO2022122167A1 (fr) Médicament pour la prévention ou le traitement d'états pathologiques de la peau humaine (i)
WO2022122122A1 (fr) Médicament pour lutter contre des états inflammatoires de la peau humaine (i)
EP3941434A1 (fr) Peptides de plante et leurs applications (ii)
WO2022128051A1 (fr) Médicament pour lutter contre des états inflammatoires de la peau humaine (ii)
WO2022171292A1 (fr) Médicament pour la prévention et le traitement de l'hyperpigmentation
WO2022128054A1 (fr) Médicament pour lutter contre des états inflammatoires de la peau humaine (iv)
WO2022128050A1 (fr) Médicament pour lutter contre l'inflammation et la douleur
WO2022128048A1 (fr) Médicament pour la prévention ou le traitement d'états pathologiques de la peau humaine
WO2022128052A1 (fr) Médicament pour lutter contre des états inflammatoires de la peau humaine
WO2022128057A1 (fr) Médicament pour la prévention et le traitement de la dégradation du collagène dans un tissu conjonctif humain
EP4245292A1 (fr) Additif pour écrans solaires
EP4245291A1 (fr) Additif pour écrans solaires
WO2022111829A1 (fr) Huiles essentielles d'agrumes destinées à être utilisées comme médicament pour obtenir une autophagie induite, augmentée et/ou accélérée dans des kératinocytes humains
WO2022218505A1 (fr) Mélange de parfum à base d'isocitronellol
WO2023175129A1 (fr) Additif pour écrans solaires
WO2024061476A1 (fr) Méthode pour prévenir, atténuer et/ou traiter des affections cutanées induites par ptgs2 et des dysfonctions associées
WO2022214187A1 (fr) Base d'emulsion huile/eau et emulsions la comprenant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20812023

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20812023

Country of ref document: EP

Kind code of ref document: A1